Top Industry Leaders in the Dermatophytic Onychomycosis Treatment Market
Latest Dermatophytic Onychomycosis Treatment Companies Update:
Alembic Pharmaceuticals Limited: In April 2023, Alembic received tentative FDA approval for its Efinaconazole Topical Solution, a new antifungal treatment for onychomycosis. This could significantly expand their market reach.
Lucira Therapeutics: In December 2023, Lucira announced positive Phase 3 trial results for its LCLX-101, a novel topical antifungal treatment for onychomycosis. This could potentially usher in a new class of treatments.
Bausch Health Companies Inc.: In September 2023, Bausch Health announced a partnership with Pfizer to develop and commercialize a new oral antifungal medication for onychomycosis. This collaboration combines expertise from two major players in the market.
Galderma: In July 2023, Galderma launched a new topical antifungal cream for onychomycosis, Kerydin MAX. This new formulation offers improved efficacy and patient comfort.
List of Dermatophytic Onychomycosis Treatment Key companies in the market
- Bausch Health Companies Inc.
- Pfizer Inc.
- Galderma
- GlaxoSmithKline plc
- Janssen Pharmaceuticals, Inc.
- Cipla Inc.
- Kaken pharmaceuticals Co., Ltd.